Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**3'-Deoxyguanosine** is a synthetic purine nucleoside analog in which the ribose sugar of guanosine lacks a hydroxyl group at the 3' position. It is classified as a member of the guanosines and purine nucleosides. This compound acts primarily as an inhibitor of RNA-directed RNA polymerase (EC 2.7.7.48), interfering with transcription processes[3][5][6]. It can also bind to and inhibit purine nucleoside phosphorylase[2][4], an enzyme involved in nucleotide metabolism. As such, it has been studied for its potential antitumor activity—mainly through inhibition of DNA synthesis and induction of apoptosis—and for possible antiviral or anti-infective effects due to its ability to impair viral replication[1][6]. Its use remains experimental; it is not approved for clinical use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3'-deoxyguanosine.